Oculinea, Inc. and Trican Biotechnology based in San Francisco, Ca, and New Taipei City, Taiwan on July 1st, 2025 jointly announced a research collaboration and exclusive option and license agreement to develop a novel ophthalmology implant using antibodies from Trican.
The asset under evaluation is a bispecific antibody targeting overexpressed drivers in retinal diseases. Under the terms of the agreed-upon collaboration, Oculinea will be responsible for research and development of drug-device products incorporating this antibody. Trican will support bispecific antibody generation.
Congratulations to Robert Bhisitkul, MD PhD, Professor of Ophthalmology, UCSF and cofounder of Oculinea.